Luye Pharmaceutical's new drug LY03010 may improve treatment...

Luye Pharmaceutical's new drug LY03010 may improve treatment compliance and reduce recurrence in patients with schizophrenia. The company has a strategic layout and superior products in the field of CNS treatment, showing ambition to further develop this field. The superior R&D, clinical registration, supply chain and commercialization capabilities established globally prepare for the global commercialization of new products in the future.